Daratumumab effectively delays multiple myeloma relapse by monitoring minimal residual disease, offering hope for improved ...

Trials enrolling patients with relapsed leukemia, lymphoma and brain cancers, respectively, report early data showing ...

The vaccine is designed to be given in three doses and could be used both as a treatment and a preventive measure, especially ...

About 15 months after breaking ground in earnest, Geisinger’s state-of-the-art cancer center in the borough will welcome its ...

Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 evaluating sacituzumab govitecan plus pembrolizumab in metastatic ...

The trial of a new drug, bexobrutideg, shows promising results for chronic lymphocytic leukemia patients previously treated ...

In CAR T-cell therapy for diffuse large B-cell lymphoma, distinct archetypes could guide personalized treatment decisions.

Each year, ECU Health and the Department of Pediatrics Hematology/Oncology at the Brody School of Medicine at East Carolina ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...

Researchers sought to determine whether a reduced dose of apixaban would be as effective as using full-dose apixaban in preventing recurrent VTE in patients with active cancer.